ANDA 217987, held by Cipla. Vasopressin.
As of Nov 15, 2026, ANDA 217987 (Vasopressin), held by Cipla, was first approved by FDA on Dec 6, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 6, 2023 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Vasopressin20UNITS/100ML (0.2UNITS/ML) ยท solution;intravenous | Vasopressin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
